{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T07:20:00Z","timestamp":1782890400680,"version":"3.54.5"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>\n                      Based on real-world clinical data, this study aims to evaluate the differences in eradication efficacy among various\n                      <jats:italic>H. pylori<\/jats:italic>\n                      treatment regimens and the impact of prescription appropriateness on treatment outcomes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This single-center retrospective study included 897 patients with confirmed\n                      <jats:italic>H. pylori<\/jats:italic>\n                      infection (September 2022\u2013September 2025). Eradication rates were compared among dual, triple, and bismuth-containing quadruple therapies, stratified by prescription appropriateness per 2022 Chinese guidelines. Multivariable logistic regression and stratified analyses were performed to assess factors associated with eradication success and follow-up adherence.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Overall ITT and PP eradication rates were 79.04 and 90.23%, respectively. Quadruple therapy achieved the highest rates (ITT: 81.42%; PP: 93.76%), outperforming dual and triple therapies. Prescription appropriateness significantly affected eradication in the quadruple therapy group (\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&amp;lt;\u202f0.01). In quadruple therapy, female was associated with higher eradication success (OR\u202f=\u202f2.53, 95% CI: 1.15\u20135.73). In the inappropriate dual therapy subgroup, amoxicillin dose (&amp;lt;2.0\u202fg vs. \u22652.0\u202fg\/day) did not significantly alter eradication rates. Older patients and those using TCM demonstrated better follow-up compliance.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Clinical practice should prioritize guideline-recommended regimens and standards; however, actual eradication effectiveness may vary depending on the regimen selected. Among these, bismuth-containing quadruple therapy should be the first-line treatment of choice and should be used in strict accordance with guideline standards.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1868250","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T05:39:32Z","timestamp":1782884372000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of eradication efficacy and optimization strategies for Helicobacter pylori infection based on real-world data: a multivariable retrospective study"],"prefix":"10.3389","volume":"13","author":[{"given":"Ziqi","family":"He","sequence":"first","affiliation":[{"name":"The Second Clinical School of Guangzhou University of Chinese Medicine","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linde","family":"He","sequence":"additional","affiliation":[{"name":"The Second Clinical School of Guangzhou University of Chinese Medicine","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaliu","family":"Qu","sequence":"additional","affiliation":[{"name":"The Second Clinical School of Guangzhou University of Chinese Medicine","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiting","family":"Zheng","sequence":"additional","affiliation":[{"name":"The Second Clinical School of Guangzhou University of Chinese Medicine","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leyi","family":"Dou","sequence":"additional","affiliation":[{"name":"The Second Clinical School of Guangzhou University of Chinese Medicine","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shijuan","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenhao","family":"Ye","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaoyuan","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/S2468-1253(23)00070-5","article-title":"Global prevalence of Helicobacter pylori infection between 1980 and 2022: a systematic review and meta-analysis","volume":"8","author":"Li","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"e180","DOI":"10.1016\/S2214-109X(19)30488-7","article-title":"Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis","volume":"8","author":"De Martel","year":"2020","journal-title":"Lancet Glob Health"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"3250","DOI":"10.1038\/s41591-024-03153-w","article-title":"Gastric cancer prevention by community eradication of Helicobacter pylori: a cluster-randomized controlled trial","volume":"30","author":"Pan","year":"2024","journal-title":"Nat Med"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.14309\/ajg.0000000000002968","article-title":"ACG clinical guideline: treatment of Helicobacter pylori infection","volume":"119","author":"Chey","year":"2024","journal-title":"Am J Gastroenterol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1097\/MCG.0000000000001719","article-title":"Helicobacter pylori world gastroenterology organization global guideline","volume":"57","author":"Katelaris","year":"2023","journal-title":"J Clin Gastroenterol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"2899","DOI":"10.1097\/CM9.0000000000002546","article-title":"2022 Chinese national clinical practice guideline on Helicobacter pylori eradication treatment","volume":"135","author":"Zhou","year":"2022","journal-title":"Chin Med J"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"745","DOI":"10.3760\/cma.j.cn311367-20220929-00479","article-title":"Chinese guideline for the treatment of Helicobacter pylori infection","volume":"42","year":"2022","journal-title":"Chin J Dig"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1053\/j.gastro.2021.04.012","article-title":"Comparative effectiveness of multiple different first-line treatment regimens for Helicobacter pylori infection: a network meta-analysis","volume":"161","author":"Rokkas","year":"2021","journal-title":"Gastroenterology"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"e674","DOI":"10.1016\/S2666-7568(22)00186-6","article-title":"Comparing clinical trial population representativeness to real-world populations: an external validity analysis encompassing 43 895 trials and 5 685 738 individuals across 989 unique drugs and 286 conditions in England","volume":"3","author":"Tan","year":"2022","journal-title":"Lancet Healthy Longev"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/S2468-1253(23)00281-9","article-title":"Primary antibiotic resistance of Helicobacter pylori in the Asia-Pacific region between 1990 and 2022: an updated systematic review and meta-analysis","volume":"9","author":"Hong","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1136\/gutjnl-2020-321372","article-title":"European registry on Helicobacter pylori management (hp-EuReg): patterns and trends in first-line empirical eradication prescription and outcomes of 5 years and 21 533 patients","volume":"70","author":"Nyssen","year":"2021","journal-title":"Gut"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1080\/14656566.2020.1845649","article-title":"An update on current and advancing pharmacotherapy options for the treatment of H. pylori infection","volume":"22","author":"Georgopoulos","year":"2021","journal-title":"Expert Opin Pharmacother"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"e12889","DOI":"10.1111\/hel.12889","article-title":"Diagnosis and treatment of Helicobacter pylori infection by physicians in China: a nationwide cross-sectional study","volume":"27","author":"Song","year":"2022","journal-title":"Helicobacter"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"e12998","DOI":"10.1111\/hel.12998","article-title":"Twice-daily intake of bismuth-based quadruple therapy for first-line Helicobacter pylori eradication: a retrospective study on 10-day, 14-day, and half-dose antibiotic therapy","volume":"28","author":"Lee","year":"2023","journal-title":"Helicobacter"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s13099-025-00741-0","article-title":"Vonoprazan vs. high-dose esomeprazole in bismuth-containing quadruple therapy for Helicobacter pylori rescue treatment: a retrospective cohort study","volume":"17","author":"Qian","year":"2025","journal-title":"Gut Pathogens"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"2627","DOI":"10.2147\/IJGM.S456865","article-title":"Eradication rate and factors influencing Helicobacter pylori infection clearance using standard triple therapy at a single Centre in jazan region, Saudi Arabia: a retrospective study","volume":"17","author":"Darraj","year":"2024","journal-title":"Int J Gen Med"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1093\/infdis\/jiag059","article-title":"Comparative analysis of high-dose dual therapies in first-line Helicobacter pylori eradication: an inverse probability of treatment-weighted multicenter study","volume":"233","author":"Kong","year":"2026","journal-title":"J Infect Dis"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1080\/00325481.2022.2105094","article-title":"Impact of insufficient doses of medications on Helicobacter pylori eradication: a retrospective observational study","volume":"134","author":"Shi","year":"2022","journal-title":"Postgrad Med"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1111\/apt.70535","article-title":"Review article: classic bismuth quadruple therapy for Helicobacter pylori infection\u2014questions focused on clinical practice","volume":"63","author":"Gisbert","year":"2026","journal-title":"Aliment Pharmacol Ther"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1136\/gutjnl-2022-327745","article-title":"Management of Helicobacter pylori infection: the Maastricht VI\/Florence consensus report","volume":"71","author":"Malfertheiner","year":"2022","journal-title":"Gut"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"5033","DOI":"10.2147\/IDR.S418482","article-title":"Prevalence of Helicobacter pylori antibiotic resistance in patients enrolled in Guangzhou, China","volume":"16","author":"Deng","year":"2023","journal-title":"Infect Drug Resist"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"100451","DOI":"10.1016\/j.focus.2025.100451","article-title":"Impact of sample size and its estimation in medical research","volume":"5","author":"Gan","year":"2025","journal-title":"AJPM Focus"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"e13044","DOI":"10.1111\/hel.13044","article-title":"Concentration-dependent effect of amoxicillin against clinical strains of Helicobacter pylori","volume":"29","author":"Kaouah","year":"2024","journal-title":"Helicobacter"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1016\/j.cgh.2024.01.022","article-title":"Efficacy and safety of vonoprazan-amoxicillin dual regimen with varying dose and duration for Helicobacter pylori eradication: a multicenter, prospective, randomized study","volume":"22","author":"Peng","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1136\/gutjnl-2024-332804","article-title":"Evolution of the use, effectiveness and safety of bismuth-containing quadruple therapy for Helicobacter pylori infection between 2013 and 2021: results from the European registry on H. pylori management (hp-EuReg)","volume":"74","author":"Olmedo","year":"2025","journal-title":"Gut"},{"key":"ref26","doi-asserted-by":"crossref","DOI":"10.1002\/9780470975503","volume-title":"Biological Chemistry of Arsenic, Antimony and Bismuth","author":"Sun","year":"2010"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.3390\/ijms25031600","article-title":"Bioactive bismuth compounds: is their toxicity a barrier to therapeutic use?","volume":"25","author":"Gon\u00e7alves","year":"2024","journal-title":"Int J Mol Sci"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1046\/j.1523-5378.2000.00028.x","article-title":"Solubility, absorption, and anti\u2013 Helicobacter pylori activity of bismuth subnitrate and colloidal bismuth subcitrate: in vitro data do not predict in vivo efficacy","volume":"5","author":"Phillips","year":"2000","journal-title":"Helicobacter"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1111\/j.1574-6968.2011.02239.x","article-title":"Steroid hormones as bactericidal agents to Helicobacter pylori: anti- H. pylori action of steroids","volume":"318","author":"Hosoda","year":"2011","journal-title":"FEMS Microbiol Lett"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"1556683","DOI":"10.3389\/fimmu.2025.1556683","article-title":"Estrogen and bacterial infection","volume":"16","author":"Hong","year":"2025","journal-title":"Front Immunol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"e074188","DOI":"10.1136\/bmjopen-2023-074188","article-title":"Efficacy and safety of seven chinese patent medicines combined with conventional triple\/quadruple therapy for Helicobacter pylori -positive peptic ulcers: a systematic review and network meta-analysis","volume":"14","author":"Jiang","year":"2024","journal-title":"BMJ Open"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"10781","DOI":"10.12998\/wjcc.v9.i35.10781","article-title":"Application of traditional Chinese medicine in treatment of Helicobacter pylori infection","volume":"9","author":"Li","year":"2021","journal-title":"World J Clin Cases"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.21037\/atm-22-5421","article-title":"The comparative efficacy and safety of 9 traditional Chinese medicines combined with standard quadruple therapy for Helicobacter pylori-associated gastritis: a systematic review and network meta-analysis","volume":"10","author":"Bao","year":"2022","journal-title":"Ann Transl Med"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1868250\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T05:39:34Z","timestamp":1782884374000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1868250\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":33,"alternative-id":["10.3389\/fmed.2026.1868250"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1868250","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]},"article-number":"1868250"}}